Radiopharmaceuticals, which are medicinal products containing radioactive isotopes, have become essential tools in both diagnostic imaging and therapeutic treatments. The manufacturing of radiopharmaceuticals involves a series of intricate processes, including production, quality control, release, and delivery. To ensure that all manufactured radiopharmaceuticals are of the highest quality, it is crucial to adhere to Good Manufacturing Practices (GMP) throughout the entire process until the delivery stage. In addition to GMP compliance, the manufacturing and production of radiopharmaceuticals, whether in-house or on a large commercial scale, should also comply with guidelines set by the World Health Organization (WHO), European GMP rules, FDA regulations, and Eurasian Economic Union GMP rules. These guidelines are in place to ensure the safe production and release of radiopharmaceuticals. Radiopharmaceuticals can take various forms, with the majority being administered intravenously in the form of solutions. This article will delve deep into the manufacturing practices of radiopharmaceuticals, shedding light on the bright prospects of theranostic radiopharmaceuticals, a pioneering approach that integrates therapeutic and diagnostic techniques. It will also highlight the significance of complete adherence to Good Manufacturing Practices (GMP) to ensure the production of safe and top-notch radiopharmaceutical products that benefit patients.